Maxim - Immutep Provides Corporate Update, Data Points Ahead in 2019
April 30th 2019
analyst reports
goetzpartners securities - Unlocking the value of LAG-3 in autoimmunity
This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.
